Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies with a PNMT inhibitor.

J W Dubb, R M Stote, F Alexander

    Clinical Pharmacology and Therapeutics
    |June 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET.

    Journal of neuro-oncology·2018
    Same author

    Local weighting of nanometric track structure properties in macroscopic voxel geometries for particle beam treatment planning.

    Physics in medicine and biology·2015
    Same author

    Factors influencing the motility of the perfused horse intestine.

    Quarterly journal of experimental physiology and cognate medical sciences·2014
    Same author

    Experiments on the horse stomach.

    Quarterly journal of experimental physiology and cognate medical sciences·2014
    Same author

    Ileal pouch-anal anastomosis in children with ulcerative colitis.

    Inflammatory bowel diseases·2013
    Same author

    Training principles in psychosomatic medicine.

    The American journal of orthopsychiatry·2010
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    DCTQ, a phenylethanolamine N-methyltransferase (PNMT) inhibitor, showed no significant clinical effects in human studies. Acute PNMT inhibition under resting conditions appears safe and well-tolerated in humans.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Endocrinology

    Background:

    • Phenylethanolamine N-methyltransferase (PNMT) plays a role in catecholamine synthesis in the adrenal medulla and central nervous system (CNS).
    • DCTQ (SK&F 64139) is a known potent inhibitor of PNMT.

    Purpose of the Study:

    • To evaluate the safety and clinical effects of DCTQ in humans through single-dose Phase I studies.
    • To determine achievable plasma concentrations of DCTQ in human subjects.

    Main Methods:

    • Single-dose Phase I clinical trial in human participants.
    • Administration of DCTQ and monitoring of plasma drug levels.
    • Assessment of clinical changes, blood pressure, and CNS symptoms.
    • Measurement of resting plasma and urinary catecholamines.

    Related Experiment Videos

    Main Results:

    • Achieved high plasma DCTQ levels (up to 6.26 microgram/ml) without significant adverse events.
    • No significant alterations in blood pressure or CNS-related symptoms were observed.
    • Resting plasma and urinary catecholamine levels remained unchanged post-administration.

    Conclusions:

    • Acute inhibition of PNMT by DCTQ in humans under resting conditions is well-tolerated.
    • The study suggests that PNMT inhibition has minimal acute clinical impact in the absence of physiological stress.